Evotec (NASDAQ:EVO) Shares Gap Down – Should You Sell?

Evotec SE (NASDAQ:EVO)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $3.41, but opened at $3.29. Evotec shares last traded at $3.29, with a volume of 4,840 shares.

Evotec Stock Down 0.3 %

The stock has a 50 day moving average price of $4.07 and a two-hundred day moving average price of $4.10. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.

Institutional Trading of Evotec

A number of institutional investors have recently bought and sold shares of EVO. BNP Paribas Financial Markets acquired a new stake in Evotec during the 4th quarter worth $27,000. CSS LLC IL acquired a new stake in shares of Evotec in the fourth quarter valued at about $50,000. Bank of America Corp DE lifted its position in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after acquiring an additional 9,289 shares during the period. Lighthouse Investment Partners LLC purchased a new stake in Evotec during the fourth quarter worth $166,000. Finally, DCF Advisers LLC boosted its position in shares of Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock worth $956,000 after buying an additional 12,816 shares in the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.